A box of Plaquenil, an anti-malaria drug hydroxychloroquine made by Sanofi, used for years to treat malaria and autoimmune disorders.
Alain Pitton | NurPhoto | Getty Images
French drugmaker Sanofi said Friday it is suspending recruitment of new patients for its clinical trials looking at anti-malaria drug hydroxychloroquine as a potential treatment for the coronavirus.
The company is also putting a hold on supplying the drug for off-label use to treat Covid-19 until safety concerns are cleared by the World Health Organization.
“Patient safety is Sanofi’s primary focus,” a Sanofi spokesperson said in a statement to CNBC. “In line with